resveratrol has been researched along with Pulmonary Hypertension in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Dhoble, S; Patravale, V | 1 |
| Hu, Z; Liu, X; Zhou, H | 1 |
| Li, C; Long, J; Peng, G; Xiao, P; Yang, H; Zeng, X | 1 |
| Huang, JA; Jiang, JH; Liu, YY; Wang, CG; Zeng, DX; Zhang, WY | 1 |
| Chen, D; Chen, Y; Du, G; Fang, L; Guo, J; Liu, S; Yuan, T | 1 |
| Cao, W; Fan, Y; Fang, K; Jia, X; Liu, L; Liu, T; Song, Y; Sun, X; Tu, Y; Wan, L; Wang, Y; Xiang, C; Yu, D; Yu, L | 1 |
| Chai, L; Chen, Y; Feng, W; Li, M; Li, S; Liu, P; Shi, W; Wang, J; Wang, Q; Yan, X; Zhai, C; Zhang, Q; Zhu, Y | 1 |
| Hu, CP; Li, TB; Liu, B; Luo, XJ; Ma, QL; Peng, J; Yang, ZB; Zhang, GG; Zhang, JJ; Zhang, XJ | 1 |
| Calvert, AE; Chen, B; Chicoine, LG; Meng, X; Slutzky, JL; Xue, J | 1 |
| Chen, HZ; Jia, YY; Li, MT; Liu, DP; Liu, JJ; Liu, YT; Tian, Z; Wang, Q; Zeng, XF; Zhou, S | 1 |
| Dong, H; Dong, M; Li, Y; Li, Z; Liu, M; Liu, Y; Luo, Y; Niu, W; Wang, Y; Xu, D; Zhang, B; Zhao, P | 1 |
| Liu, B; Luo, XJ; Peng, J; Peng, JJ; Xu, JY | 1 |
| Chicoine, LG; Lucchesi, PA; Stewart, JA | 1 |
| Ballabh, P; Csiszar, A; de Cabo, R; Gupte, S; Hu, F; Labinskyy, N; Losonczy, G; Mathew, R; Olson, S; Pinto, JT; Podlutsky, A; Ungvari, Z; Wolin, MS; Wu, JM | 1 |
| Chan, C; Cheng, D; Chun, C; Dan, Y; Fangyou, Y; Honglei, X; Lehe, Y; Liangxing, W; Qi, Z; Weixi, Z; Xiaoying, H; Xueding, C; Yang, W; Yuanyuan, L; Zhoucang, Z | 1 |
| Anderson, T; Campen, MJ; Candelaria, G; Hesterman, J; Hoppin, J; Irwin, D; Lucas, S; Norenberg, J; Paffett, ML | 1 |
1 review(s) available for resveratrol and Pulmonary Hypertension
| Article | Year |
|---|---|
NADPH oxidase: its potential role in promotion of pulmonary arterial hypertension.
Topics: Acetophenones; Animals; Humans; Hypertension, Pulmonary; NADPH Oxidases; Onium Compounds; Resveratrol; Stilbenes | 2017 |
15 other study(ies) available for resveratrol and Pulmonary Hypertension
| Article | Year |
|---|---|
SIRT 1 Activator Loaded Inhaled Antiangiogenic Liposomal Formulation Development for Pulmonary Hypertension.
Topics: Angiogenesis Inhibitors; Humans; Hypertension, Pulmonary; Liposomes; Powders; Resveratrol; Sirtuins | 2022 |
Resveratrol attenuates chronic pulmonary embolism-related endothelial cell injury by modulating oxidative stress, inflammation, and autophagy.
Topics: Animals; Autophagy; Endothelial Cells; Humans; Hypertension, Pulmonary; Inflammation; Oxidative Stress; Pulmonary Artery; Pulmonary Embolism; Rats; Resveratrol; Thrombin | 2022 |
Protective effects of resveratrol and SR1001 on hypoxia-induced pulmonary hypertension in rats.
Topics: Animals; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Hypertension, Pulmonary; Hypoxia; Male; Protein Phosphatase 1; Pulmonary Artery; Rats; Resveratrol; rhoA GTP-Binding Protein; Sulfonamides; Th17 Cells; Thiazoles; Treatment Outcome | 2020 |
Resveratrol prevented experimental pulmonary vascular remodeling via miR-638 regulating NR4A3/cyclin D1 pathway.
Topics: Animals; Cell Proliferation; Cells, Cultured; Cyclin D1; Disease Models, Animal; DNA-Binding Proteins; Hypertension, Pulmonary; Male; MicroRNAs; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nerve Tissue Proteins; Pulmonary Artery; Rats, Wistar; Resveratrol; Signal Transduction; Vascular Remodeling | 2020 |
Systematic analysis of molecular mechanism of resveratrol for treating pulmonary hypertension based on network pharmacology technology.
Topics: Antioxidants; Data Mining; Gene Regulatory Networks; Humans; Hypertension, Pulmonary; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Proto-Oncogene Mas; Resveratrol; Sirtuin 1; Technology, Pharmaceutical | 2020 |
Resveratrol Protects Against Pulmonary Arterial Hypertension in Rats via Activation of Silent Information Regulator 1.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blood Pressure; Cell Hypoxia; Cell Movement; Cell Proliferation; Cells, Cultured; Down-Regulation; Heterocyclic Compounds, 4 or More Rings; Hypertension, Pulmonary; Male; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Muscle, Smooth, Vascular; Pulmonary Artery; Rats; Rats, Wistar; Resveratrol; Sirtuin 1; Stilbenes; Vascular Remodeling | 2017 |
Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-κB activation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Hypertension, Pulmonary; Male; Monocrotaline; NF-kappa B; Phosphotransferases (Alcohol Group Acceptor); Rats; Rats, Sprague-Dawley; Resveratrol; Signal Transduction; Stilbenes; Vascular Remodeling | 2018 |
Inhibition of NOX/VPO1 pathway and inflammatory reaction by trimethoxystilbene in prevention of cardiovascular remodeling in hypoxia-induced pulmonary hypertensive rats.
Topics: Animals; Hemeproteins; Hypertension, Pulmonary; Hypoxia; Inflammation; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Peroxidases; Random Allocation; Rats; Rats, Sprague-Dawley; Resveratrol; Signal Transduction; Stilbenes; Ventricular Remodeling | 2014 |
Resveratrol prevents hypoxia-induced arginase II expression and proliferation of human pulmonary artery smooth muscle cells via Akt-dependent signaling.
Topics: Animals; Arginase; Cell Proliferation; Cells, Cultured; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Myocytes, Smooth Muscle; Proto-Oncogene Proteins c-akt; Rats; Resveratrol; Stilbenes | 2014 |
Regulation of Cell Cycle Regulators by SIRT1 Contributes to Resveratrol-Mediated Prevention of Pulmonary Arterial Hypertension.
Topics: Animals; Cell Cycle; Cell Cycle Proteins; Dose-Response Relationship, Drug; Hypertension, Pulmonary; Male; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Resveratrol; Sirtuin 1; Stilbenes; Treatment Outcome; Vasodilator Agents | 2015 |
Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats.
Topics: Animals; Antioxidants; Hypertension, Pulmonary; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Inflammation; NF-E2-Related Factor 2; Random Allocation; Rats; Reactive Oxygen Species; Resveratrol; Stilbenes; Thioredoxins | 2016 |
Is resveratrol the magic bullet for pulmonary hypertension?
Topics: Animals; Blood Pressure; Cell Proliferation; Dose-Response Relationship, Drug; Endothelium, Vascular; Gene Expression; Hypertension, Pulmonary; Models, Biological; Monocrotaline; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Pulmonary Artery; Rats; Resveratrol; Stilbenes; Tumor Necrosis Factors; Vasodilation; Vasodilator Agents | 2009 |
Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Blood Pressure; Blotting, Western; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Gene Expression; Hypertension, Pulmonary; Interleukin-6; Male; Monocrotaline; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Resveratrol; Reverse Transcriptase Polymerase Chain Reaction; Stilbenes; Tumor Necrosis Factors; Vasodilation; Vasodilator Agents | 2009 |
Resveratrol downregulates acute pulmonary thromboembolism-induced pulmonary artery hypertension via p38 mitogen-activated protein kinase and monocyte chemoattractant protein-1 signaling in rats.
Topics: Animals; Blotting, Western; Chemokine CCL2; Down-Regulation; Enzyme Inhibitors; Fluorescent Antibody Technique; Hypertension, Pulmonary; Imidazoles; Immunohistochemistry; Indicators and Reagents; Male; p38 Mitogen-Activated Protein Kinases; Pulmonary Embolism; Pyridines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Resveratrol; RNA, Messenger; Signal Transduction; Stilbenes | 2012 |
Longitudinal in vivo SPECT/CT imaging reveals morphological changes and cardiopulmonary apoptosis in a rodent model of pulmonary arterial hypertension.
Topics: Animals; Annexins; Apoptosis; Blood Pressure; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Heart Ventricles; Humans; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Myocardium; Perfusion; Rats; Rats, Sprague-Dawley; Resveratrol; Stilbenes; Systole; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Ventricular Remodeling | 2012 |